Novo Nordisk A/S Class B Overview
Novo Nordisk A/S Class B (NONOF) has a ROE of 52.62%, above the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow52.62%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for NONOF is 52.62%. That is above the Healthcare sector average of 11.15%. Investors often review this figure alongside Novo Nordisk A/S Class B's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, NONOF currently prints 52.62% for ROE, while the sector average sits near 11.15%. That is roughly 371.8% above the sector mean. Large gaps often invite a closer look at Novo Nordisk A/S Class B's growth, margins, and balance sheet.
Return on Equity shows how effectively Novo Nordisk A/S Class B converts resources into returns. At 52.62%, NONOF may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting NONOF's ROE (52.62%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Novo Nordisk A/S Class B's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
